Tag: Health

NEOVIVA, SWITZERLAND’S FIRST ADDICTION CLINIC OFFERING GUARANTEE

by jezzabellemente, posted in Uncategorized

LUCERNE, Switzerland, Jan 21 (Bernama-GLOBE NEWSWIRE) — Neoviva, a leading luxury rehab centre launches Switzerland’s first and only assurance programme in addiction treatment. With a structured and tailored approach, Neoviva’s programme addresses the unique needs of each client, blending cutting-edge therapeutic methods with comprehensive aftercare. The Neoviva Guarantee is a testament to the effectiveness of their personalised Signature Programme and reflects confidence in the programme’s ability to help clients achieve sustainable recovery.

“Our track record speaks for itself, with countless success stories of lasting recovery. The Neoviva Guarantee is our way of putting action behind our words. We’re so convinced of our programme’s efficacy that we’re willing to stand by our clients long after they leave our facility. This isn’t just treatment; it’s a lifelong partnership in recovery,” states Fenina Erpf, CEO and Co-Founder of NEOVIVA, alongside Oliver Neubert, Founder of NEOVIVA.

Clients who complete a minimum of six weeks of Neoviva’s Signature programme and adhere to the 30-week continuing care plan are eligible for the Guarantee. Should a client relapse within one year of completing the programme, they may return for up to four weeks of additional intensive treatment at no extra cost.*

Nestled on the tranquil shores of Lake Lucerne, NEOVIVA’s luxury rehab facility blends world-class care with an exclusive and serene environment. Housed within a real-life hotel setting, our clinic offers the perfect balance of comfort, privacy, and discretion, ensuring a supportive space for recovery. This unique setting empowers clients with the tools and strategies needed to navigate life beyond treatment, all while immersed in the breathtaking beauty of the Swiss Alps.

About Neoviva:

Neoviva is a luxury rehab centre in Switzerland that offers personalised treatment plans for mental health and addiction treatment. With pioneering methodologies, a high staff-to-client ratio, and a commitment to profound personal transformation, Neoviva is more than a rehab centre—it is a life-changing experience for those seeking lasting recovery.

*Terms and conditions apply.

A photo accompanying this announcement is available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/22e5d7be-00e5-4d4c-9f88-fde0ffc48718

For more information, please contact:

Fenina Erpf

CEO & Co-Founder

fenina.erpf@neoviva.com

6354 Vitznau

Switzerland

Phone: +41 58 100 08 00

SOURCE: NEOVIVA AG

–BERNAMA

ZENAS BIOPHARMA TO PARTICIPATE IN UPCOMING HEALTHCARE INVESTOR CONFERENCES

by jezzabellemente, posted in Uncategorized

WALTHAM, Mass, 8 Nov (Bernama-GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences:

  • Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA
  • Jefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in London
  • Citi’s 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FL
  • Evercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL

Live webcasts and archived replays of the Company’s presentations at the Jefferies, Citi and Evercore conferences can be accessed under “Events and Presentations” in the Investors and Media section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners
Zenas@argotpartners.com

SOURCE : Zenas BioPharma (USA) LLC

KOLMAR BNH STRIVES FOR GLOBAL EXPANSIONS BUILDING ON HEMOHIM’S RECOGNITION

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Oct 22 (Bernama) — Kolmar BNH immune-boosting health supplement, ‘HemoHim’, has earned international recognition for its quality from both the United States (US) Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), enhancing its credibility in the global marketplace.

In a statement, Kolmar BNH announced its Sejong plant obtained a No Action Indicated (NAI) classification following an inspection by the US FDA in September.

This classification, which confirms that the facility fully complies with US Current Good Manufacturing Practice (cGMP) standards for quality control, has further intensified Kolmar BNH’s competitiveness as a leading global Original Development Manufacturer (ODM) in the health supplement industry.

“We are committed to enhancing our competitiveness in global markets through ongoing quality innovation and additional global certifications, with HemoHim at the forefront of our efforts,” said an official from Kolmar BNH.

The FDA inspection was conducted to evaluate the company’s quality management capabilities, particularly in response to the increasing exports of HemoHim to the US.

The NAI classification reflects a comprehensive evaluation of key factors, including manufacturing processes, hygiene standards, quality control procedures, and employee training.

Meanwhile, HemoHim’s quality has previously been recognised in Australia, where the Sejong plant obtained Good Manufacturing Practice (GMP) certification from the TGA in 2021.

To meet the Australian TGA’s GMP standards, Kolmar BNH implemented a Standard Operating Procedure (SOP) at the Sejong plant that aligns with international GMP guidelines for pharmaceutical production and quality control.

Building on its success with FDA and TGA certifications, Kolmar BNH plans to expedite HemoHim’s expansion into global markets.

Launched in 2006 and distributed by Atomy, HemoHim is Korea’s first individually approved immune-boosting supplement, made from Korean natural ingredients, with the product currently exported to approximately 20 countries.

— BERNAMA

GRADIANT’S FOREVERGONE PROVEN TO COMPLETELY WIPE OUT PFAS IN INDUSTRIAL USE

by jezzabellemente, posted in Uncategorized


KUALA LUMPUR, Oct 9 (Bernama) — Gradiant, a global solutions provider for advanced water and wastewater treatment, has announced a major milestone in the fight against per- and polyfluoroalkyl substances (PFAS) contamination, with its ForeverGone all-in-one solution.

Working with contaminated industrial, municipal, and landfill waters, ForeverGone has been quantifiably proven, through multiple third-party accredited laboratories, reducing PFAS to levels below regulatory limits and destroying the resulting PFAS concentrate completely.

“To support the development of ForeverGone, we have made a significant investment in the Gradiant Labs’ capability to detect PFAS down to just one part per trillion, which uniquely enables us to rapidly offer customer partners the proof they seek of the effectiveness of our technology on their contaminated water,” said Gradiant Head of Technology, Steven Lam in a statement.

Meanwhile, its Global Head of Sales, Sankar Natarajan said key decision makers appreciate ForeverGone’s differentiated proposition to remove and destroy PFAS from all types of contaminated waters.

“We are experiencing an unprecedented sales velocity from first engagement to full-scale project deployment across multiple industrial sectors, including semiconductors, food & beverage, mining, and major municipal utilities, all striving to meet regulatory requirements and safeguard their communities,” he added.

This milestone in development confirms ForeverGone, introduced earlier this year, as the only all-in-one solution capable of removing and destroying PFAS on-site, eliminating the need for waste handling, landfilling, or incineration, differentiating it from conventional technologies, including granular activated carbon (GAC) and ion exchange.

The containerised ForeverGone solution is deployed quickly and commissioned on-site to effectively reduce PFAS to levels below the United States Environmental Protection Agency (EPA)’s new maximum contaminant level of 4.0 parts per trillion (ppt), and the strict limits set by European and Australian regulations.

Gradiant is actively deploying the ForeverGone solution at customer partner sites worldwide, offering them the significant advantage of all-in-one PFAS removal and destruction.

— BERNAMA